Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. During the same period in the prior year, the company earned ($0.15) earnings per share. On average, analysts expect Rigel Pharmaceuticals to post $-0.6 EPS for the current fiscal year and $-0.55 EPS for the next fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/11/01/rigel-pharmaceuticals-inc-rigl-to-release-quarterly-earnings-on-tuesday.html.
RIGL has been the topic of several research analyst reports. BMO Capital Markets reissued a “buy” rating and issued a $5.00 price objective on shares of Rigel Pharmaceuticals in a report on Monday, October 2nd. BidaskClub lowered Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. ValuEngine lowered Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 6th. Zacks Investment Research raised Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.75.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.